Ariad aims for global oncology play as it files US ponatinib NDA in CML
This article was originally published in Scrip
Ariad Pharmaceuticals is ahead of schedule with its plans to take on the $4.5 billion chronic myeloid leukaemia market. Ponatinib is key to Ariad's plans to transform itself from an innovative discovery and development enterprise to a global oncology business (scripintelligence.com, 5 June 2012).
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.